Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Surmounting Small Molecule Challenges
Natural Product-Based Techniques See Resurgence of Interest and Applicability
- Companies are developing new platforms to enhance their small molecule discovery efforts and, in turn, the molecules themselves. This is due in part to increased pressure to develop new drugs. With an estimated $20 billion of brand-name drugs going off patent this year, the biopharma industry is scrambling to find ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.